<DOC>
	<DOCNO>NCT00081289</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Chemoradiotherapy ( combine chemotherapy radiation therapy ) surgery may shrink tumor remove . Giving chemotherapy surgery may kill remain tumor cell . PURPOSE : This randomized phase II trial study two different regimen neoadjuvant chemoradiotherapy adjuvant chemotherapy compare well work treat patient undergo surgical resection locally advanced rectal cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiotherapy Adjuvant Chemotherapy Treating Patients Who Are Undergoing Surgical Resection Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate pathologic complete response rate patient locally advanced rectal cancer undergo surgical resection treat 2 different regimen neoadjuvant chemoradiotherapy adjuvant chemotherapy . - Evaluate time treatment failure pattern failure patient treat regimen . - Evaluate incidence hematologic non-hematologic grade 3-4 toxicity ( preoperatively , postoperatively , overall ) patient treat regimen . - Evaluate quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord clinical stage tumor ( T3 v T4 ) . Patients randomize 1 2 treatment arm . - Arm I : Neoadjuvant chemoradiation irinotecan : Patients receive neoadjuvant therapy comprise radiotherapy daily , 5 day week , 6 week concurrent oral capecitabine 1200 mg/m^2 daily ( 5 day week ) 6 week irinotecan IV 1 hour day 1 , 8 , 22 , 29 . Patients undergo surgical resection 4-8 week complete radiotherapy . Beginning 4-6 week surgery , patient receive adjuvant chemotherapy comprise oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour begin day 1 . Treatment repeat every 14 day total 9 course . - Arm II : Neoadjuvant chemoradiation oxaliplatin : Patients receive neoadjuvant therapy comprise radiotherapy capecitabine 1650 mg/m^2 daily arm I ( except capecitabine dose ) oxaliplatin IV 2 hour day 1 , 8 , 15 , 22 , 29 . Patients undergo surgical resection 4-8 week complete radiotherapy . Beginning 4-6 week surgery , patient receive adjuvant chemotherapy comprise oxaliplatin , leucovorin calcium , fluorouracil Arm I adjuvant chemotherapy . Treatment repeat every 14 day total 9 course . Quality life assess baseline , within 1 week completion radiotherapy , within 1 week completion adjuvant chemotherapy ( 12 month ) , 24 month . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 141 patient ( approximately 70 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma rectum Clinical stage T3 T4 disease endorectal ultrasound physical examination ( T4 lesion ) Tumor originate 12 cm anal verge No extension disease anal canal No evidence distant metastases No synchronous primary colon carcinoma except T1 lesion Potentially resectable en bloc disease PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic AST ( aspartate aminotransferase ) &lt; 2.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2.5 time ULN Bilirubin â‰¤ 1.5 time ULN No known uncontrolled coagulopathy Renal Creatinine clearance &gt; 50 mL/min Cardiovascular No congestive heart failure No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past year No clinically significant cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study treatment No concurrent serious uncontrolled infection No malabsorption syndrome No lack physical integrity upper gastrointestinal tract No evidence uncontrolled seizure , central nervous system ( CNS ) disorder , psychiatric disability , judge investigator , clinically significant , precludes give informed consent , interfere compliance oral drug intake No malignancy within past 5 year except nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ breast No serious uncontrolled medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent routine prophylactic filgrastim ( GCSF ) Chemotherapy No prior anticancer chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy pelvis No concurrent intensitymodulated radiotherapy Surgery More 4 week since prior major surgery Other More 4 week since prior participation another clinical trial No concurrent cimetidine No concurrent sorivudine brivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage II rectal cancer</keyword>
</DOC>